Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ABL1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ABL1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ABL1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ABL1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ABL1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048008 | Colorectum | FAP | platelet-derived growth factor receptor signaling pathway | 16/2622 | 56/18723 | 3.40e-03 | 2.47e-02 | 16 |
GO:00073462 | Colorectum | FAP | regulation of mitotic cell cycle | 85/2622 | 457/18723 | 3.41e-03 | 2.48e-02 | 85 |
GO:00611381 | Colorectum | FAP | morphogenesis of a branching epithelium | 39/2622 | 182/18723 | 3.98e-03 | 2.76e-02 | 39 |
GO:00018432 | Colorectum | FAP | neural tube closure | 22/2622 | 88/18723 | 4.21e-03 | 2.90e-02 | 22 |
GO:00017381 | Colorectum | FAP | morphogenesis of a polarized epithelium | 23/2622 | 94/18723 | 4.64e-03 | 3.14e-02 | 23 |
GO:00346144 | Colorectum | FAP | cellular response to reactive oxygen species | 34/2622 | 155/18723 | 4.68e-03 | 3.16e-02 | 34 |
GO:00606062 | Colorectum | FAP | tube closure | 22/2622 | 89/18723 | 4.87e-03 | 3.26e-02 | 22 |
GO:00435423 | Colorectum | FAP | endothelial cell migration | 55/2622 | 279/18723 | 5.00e-03 | 3.33e-02 | 55 |
GO:1903131 | Colorectum | FAP | mononuclear cell differentiation | 79/2622 | 426/18723 | 5.00e-03 | 3.33e-02 | 79 |
GO:19037063 | Colorectum | FAP | regulation of hemopoiesis | 69/2622 | 367/18723 | 6.01e-03 | 3.78e-02 | 69 |
GO:0016331 | Colorectum | FAP | morphogenesis of embryonic epithelium | 32/2622 | 147/18723 | 6.69e-03 | 4.13e-02 | 32 |
GO:00459311 | Colorectum | FAP | positive regulation of mitotic cell cycle | 27/2622 | 121/18723 | 8.64e-03 | 4.98e-02 | 27 |
GO:00070155 | Colorectum | CRC | actin filament organization | 104/2078 | 442/18723 | 4.75e-14 | 7.12e-11 | 104 |
GO:00071735 | Colorectum | CRC | epidermal growth factor receptor signaling pathway | 39/2078 | 108/18723 | 6.90e-12 | 5.90e-09 | 39 |
GO:00381275 | Colorectum | CRC | ERBB signaling pathway | 41/2078 | 121/18723 | 2.12e-11 | 1.59e-08 | 41 |
GO:00329705 | Colorectum | CRC | regulation of actin filament-based process | 89/2078 | 397/18723 | 5.25e-11 | 3.14e-08 | 89 |
GO:00226045 | Colorectum | CRC | regulation of cell morphogenesis | 74/2078 | 309/18723 | 9.25e-11 | 5.04e-08 | 74 |
GO:00108105 | Colorectum | CRC | regulation of cell-substrate adhesion | 57/2078 | 221/18723 | 6.94e-10 | 2.60e-07 | 57 |
GO:00510563 | Colorectum | CRC | regulation of small GTPase mediated signal transduction | 69/2078 | 302/18723 | 3.34e-09 | 9.08e-07 | 69 |
GO:00315894 | Colorectum | CRC | cell-substrate adhesion | 78/2078 | 363/18723 | 6.22e-09 | 1.49e-06 | 78 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABL1 | SNV | Missense_Mutation | | c.1375N>C | p.Tyr459His | p.Y459H | P00519 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABL1 | SNV | Missense_Mutation | | c.1819N>C | p.Glu607Gln | p.E607Q | P00519 | protein_coding | deleterious_low_confidence(0.02) | benign(0.315) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ABL1 | SNV | Missense_Mutation | rs780527035 | c.119N>G | p.Asn40Ser | p.N40S | P00519 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.97) | TCGA-AC-A3EH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ABL1 | SNV | Missense_Mutation | | c.1503C>A | p.Asp501Glu | p.D501E | P00519 | protein_coding | tolerated(0.52) | benign(0.003) | TCGA-BH-A0B3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ABL1 | SNV | Missense_Mutation | | c.268N>A | p.Asp90Asn | p.D90N | P00519 | protein_coding | deleterious(0.01) | probably_damaging(0.952) | TCGA-E2-A1LB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ABL1 | SNV | Missense_Mutation | novel | c.1471A>T | p.Met491Leu | p.M491L | P00519 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-E9-A54X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABL1 | insertion | Frame_Shift_Ins | novel | c.1125_1126insA | p.Asn377LysfsTer24 | p.N377Kfs*24 | P00519 | protein_coding | | | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ABL1 | deletion | Frame_Shift_Del | | c.2409delC | p.Arg804GlyfsTer3 | p.R804Gfs*3 | P00519 | protein_coding | | | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABL1 | insertion | Nonsense_Mutation | novel | c.104_105insCCTGGCCTCGTTGTGGAGCGGCTCGTAATCCATCAT | p.Gly35_Gly36insLeuAlaSerLeuTrpSerGlySerTerSerIleMet | p.G35_G36insLASLWSGS*SIM | P00519 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ABL1 | deletion | Frame_Shift_Del | novel | c.3216_3225delNNNNNNNNNN | p.Ser1073TrpfsTer12 | p.S1073Wfs*12 | P00519 | protein_coding | | | TCGA-B6-A2IU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | DASATINIB | DASATINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | PAZOPANIB | PAZOPANIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | GENISTEIN | GENISTEIN | 9349317 |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | inhibitor | 249565818 | | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | Nilotinib | NILOTINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | inhibitor | NILOTINIB | NILOTINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | vincristine | VINCRISTINE | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | NILOTINIB | NILOTINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | Asciminib | ASCIMINIB | |
25 | ABL1 | ENZYME, TYROSINE KINASE, TUMOR SUPPRESSOR, KINASE, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE | | AZD0530 | SARACATINIB | |